clinical implications of the change in glomerular filtration rate with adrenergic blockers in patients with morning hypertension: the japan morning surge-1 study
Clicks: 209
ID: 150557
2013
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
209 views
48 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #15 of 242 articles by views in molecular biology and evolution
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 242 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Background. The aim of this study was to clarify the relationship between the change in estimated glomerular filtration rate (eGFR) and urinary albumin by antihypertensive treatment.
Methods. We randomized 611 treated patients with morning hypertension into either an added treatment group, for whom doxazosin was added to the current medication, or a control group, who continued their current medications. We compared the change in eGFR and urinary albumin creatinine ratio (UACR) between the groups. Results. The extent of the reduction in eGFR was significantly greater in the added treatment group than in the control group (−3.83 versus −1.08 mL/min/1.73 m2, P=0.001). In multivariable analyses, the change in eGFR was positively associated with the change in UACR in the added treatment group (β=0.20, P=0.001), but not in the control group (β=−0.002, P=0.97). When the changes in eGFR were divided by each CKD stage, eGFR was significantly more decreased in stage 1 than in the other stages in the added treatment group (P<0.001), but no differences were seen in the control group (P=0.44). Conclusion. The reduction of eGFR could be seen only in the early stage of CKD, and this treatment appeared to have no negative effect on renal function.
| Reference Key |
shibasaki2013internationalclinical
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Seiichi Shibasaki;Kazuo Eguchi;Yoshio Matsui;Kazuyuki Shimada;Kazuomi Kario |
| Journal | molecular biology and evolution |
| Year | 2013 |
| DOI |
10.1155/2013/413469
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.